Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness
YC Tsai, TF Tsai - Therapeutic advances in musculoskeletal …, 2017 - journals.sagepub.com
YC Tsai, TF Tsai
Therapeutic advances in musculoskeletal disease, 2017•journals.sagepub.comAnti-interleukin (IL) therapies have emerged as a major treatment for patients with moderate-
to-severe psoriasis. This article reviews the up-to-date results of pivotal clinical trials
targeting the interleukins used for the treatment of psoriasis, including IL-1, IL-2, IL-6, IL-8, IL-
10, IL-12, IL-17, IL-20, IL-22, IL-23, IL-36 and bispecific biologics IL-17A/tumor necrosis
factor alpha (TNF-α). Cytokines involved in the circuits of psoriasis inflammation without
ongoing clinical trials are also mentioned (IL-9, IL-13, IL-15, IL-16, IL-18, IL-19, IL-21, IL-24 …
to-severe psoriasis. This article reviews the up-to-date results of pivotal clinical trials
targeting the interleukins used for the treatment of psoriasis, including IL-1, IL-2, IL-6, IL-8, IL-
10, IL-12, IL-17, IL-20, IL-22, IL-23, IL-36 and bispecific biologics IL-17A/tumor necrosis
factor alpha (TNF-α). Cytokines involved in the circuits of psoriasis inflammation without
ongoing clinical trials are also mentioned (IL-9, IL-13, IL-15, IL-16, IL-18, IL-19, IL-21, IL-24 …
Anti-interleukin (IL) therapies have emerged as a major treatment for patients with moderate-to-severe psoriasis. This article reviews the up-to-date results of pivotal clinical trials targeting the interleukins used for the treatment of psoriasis, including IL-1, IL-2, IL-6, IL-8, IL-10, IL-12, IL-17, IL-20, IL-22, IL-23, IL-36 and bispecific biologics IL-17A/tumor necrosis factor alpha (TNF-α). Cytokines involved in the circuits of psoriasis inflammation without ongoing clinical trials are also mentioned (IL-9, IL-13, IL-15, IL-16, IL-18, IL-19, IL-21, IL-24, IL-27, IL-33, IL-35, IL-37, and IL-38).
Sage Journals